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Abstract
Background: New targeted therapies and improved treatment strategies have dramatically improved the outcomes
of patients with rheumatoid arthritis (RA). However, it is unknown whether different early aggressive interventions can
induce stable remission or a low-active disease state that can be maintained with conventional synthetic
disease-modifying antirheumatic drug (csDMARD) therapy, and whether they differ in efficacy and safety. The
Nordic Rheumatic Diseases Strategy Trials And Registries (NORD-STAR) study will assess and compare (1) the
proportion of patients who achieve remission in a head-to-head comparison between csDMARD plus glucocorticoid
therapy and three different biological DMARD (bDMARD) therapies with different modes of action and (2) two
de-escalation strategies in patients who respond to first-line therapy.
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Methods/design: In a pragmatic, 80–160-week, multicenter, randomized, open-label, assessor-blinded, phase 4 study,
800 patients with early RA (symptom duration less than 24 months) are randomized 1:1:1:1 to one of four different
treatment arms: (1) aggressive csDMARD therapy with methotrexate + sulphasalazine + hydroxychloroquine + i.a.
glucocorticoids (arm 1A) or methotrexate + prednisolone p.o. (arm 1B), (2) methotrexate + certolizumab-pegol, (3)
methotrexate + abatacept, or (4) methotrexate + tocilizumab. The primary clinical endpoint is the proportion of patients
reaching Clinical Disease Activity Index (CDAI) remission at week 24. Patients in stable remission over 24 consecutive
weeks enter part 2 of the study earliest after 48 weeks. Patients not achieving sustained CDAI remission over
24 consecutive weeks, exit the study after 80 weeks. In part 2, patients are re-randomized to two different
de-escalation strategies, either immediate or delayed (after 24 weeks) tapering, followed by cessation of study
medication. All patients remain on stable doses of methotrexate. The primary clinical endpoint in part 2 is the
proportion of patients in remission (CDAI ≤2.8) 24 weeks after initiating treatment de-escalation. Radiographic
assessment will be performed regularly throughout the trial, and blood and urine samples will be stored in a
biobank for later biomarker analyses.
Discussion: NORD-STAR is the first investigator-initiated, randomized, early RA trial to compare (1) csDMARD
and three different bDMARD therapies head to head and (2) two different de-escalation strategies. The trial
has the potential to identify which treatment strategy to apply in early RA to achieve the best possible outcomes for
both patients and society.
Trial registration: NCT01491815 and NCT02466581. Registered on 8 December 2011 and May 2015, respectively.
EudraCT: 2011-004720-35
Keywords: Rheumatoid arthritis, Early treatment, Biological treatment, Aggressive conventional treatment,
Sustained remission, De-escalation strategy
Background
Rheumatoid arthritis (RA) is a common inflammatory
disorder with a reported prevalence of 0.5–1% of the
population [1]. It is characterized by progressive inflamma-
tory arthritis with joint swelling and tenderness. Over time,
structural joint damage evidenced by radiographic progres-
sion may occur and joint function diminishes [2, 3]. The
economic burden of RA is substantial with high annual
direct and indirect costs, mainly associated with lost in-
come from work [4].
During the few last decades, new pharmacologic treat-
ments and treatment strategies have been introduced,
which have dramatically improved the outcomes in RA.
Therapy with conventional synthetic disease-modifying
antirheumatic drugs (csDMARD), most commonly metho-
trexate in combination with glucocorticoids, are still first-
line treatment. Combining methotrexate with other
csDMARDs may further increase their clinical effect [5].
However, there are limited convincing data that combin-
ation treatment is superior when it comes to the preven-
tion of radiographically demonstrable damage.
In the Fin-RACo trial, sulphasalazine monotherapy,
stepwise changed to other csDMARD monotherapy if
there is an inadequate response and supplemented with
orally administered prednisolone if needed, was com-
pared with combination therapy with methotrexate,
hydroxychloroquine, sulphasalazine and orally adminis-
tered prednisolone. A significantly higher number of pa-
tients were in remission and showed less erosive disease
in the combination therapy group after 1 and 2 years [6].
Follow-up results at 5 and 11 years showed that clinical
and radiographic outcomes of the patients in the com-
bination therapy group continued to be superior to the
monotherapy group [7, 8]. The CIMESTRA trial
achieved 34–43% Disease Activity Score (DAS) remis-
sion after 1 year, increasing to 50–51% and 76–80% after
2 and 5 years, respectively, in early RA by aggressive use
of glucocorticoid injections administered via the intra-
articular (i.a.) route in addition to either monotherapy
with methotrexate or combination therapy with metho-
trexate and cyclosporine A [9–11]. The high remission
rates with this strategy were confirmed in the 2-year
OPERA trial, and in both studies radiographic progres-
sion was minimal [12].
Tight disease control with frequent patient visits and
the application of a treat-to-target approach is another
way to improve outcomes. This was demonstrated in the
TICORA study in which patients with RA of less than
5 years’ duration were treated with csDMARD therapy
and were randomized to either intensive management or
routine care. In the tight control group, more patients
reached remission and the radiographically demon-
strable erosive progression rate tended to be reduced in
the tight control group compared to the routine care
group [13].
The effect of biological disease-modifying antirheu-
matic drugs (bDMARDs) in combination with metho-
trexate in early RA is thoroughly documented in a
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number of large randomized controlled trials. Consistently,
the tumor necrosis factor (TNF) inhibitors as well as other
bDMARD treatments have shown superior clinical and
radiographic results when given in combination with
methotrexate compared to methotrexate alone [14–16].
However, bDMARD therapy is very expensive and associ-
ated with an increased rate of serious infections. Thus,
according to the standing European League Against
Rheumatism (EULAR) recommendations for the manage-
ment of rheumatoid arthritis, bDMARD treatment should
be added only after an initial trial of csDMARD treatment
[17]. No previous studies of early RA have compared the
efficacy and safety between csDMARD therapy and several
bDMARD therapies with different modes of action in a
head-to-head design.
The principle of early treatment is based on the concept
of a therapeutic window of opportunity early in the dis-
ease course, and that a delay in starting DMARD therapy
has a significant negative impact on the patient’s disease
course and mortality [18]. Patients treated early have a sig-
nificant reduction of radiographic progression, and pa-
tients with more aggressive disease seem to benefit most
from early DMARD initiation [19]. Studies have shown
that a substantial number of patients with established RA,
who have previously failed csDMARD therapy, experience
disease flare upon withdrawal of TNF inhibitors [20–23].
In patients with early RA, on the other hand, sustained
biological-free remission may be achievable [24–26]. It is
not known whether a more aggressive strategy, with the
use of bDMARDs in the initial phase, can modulate the
disease course more effectively, and further whether any
particular drug mechanism of action works better in indu-
cing remission that subsequently can be sustained with
simpler means (induction-maintenance therapy).
The main objectives of the Nordic Rheumatic Diseases
Strategy Trials And Registries (NORD-STAR) study are:
(1) to assess and compare head to head the proportion
of patients with early RA who achieve remission with
aggressive csDMARD therapy and three bDMARD ther-
apies with different modes of action and (2) to assess
and compare two alternative de-escalation strategies in
patients who respond to first-line therapy.
Methods/design
Study design
The NORD-STAR study is a pragmatic, 80–160-week,
multicentre, randomized, open-label, assessor-blinded,
multiarm, parallel, phase 4 study in early RA, conducted
at multiple centers in Denmark, Finland, Iceland, Norway
and Sweden. Flow charts of the phases of the study are
presented in Figs. 1 and 2, and a completed Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) Checklist for clinical trial protocols is
presented in Additional file 1.
The study consists of two treatment parts. In treat-
ment part 1 (TP1, Fig. 3), aggressive csDMARD therapy
is compared head to head with three different bDMARD
therapies. In treatment part 2 (TP2, Fig. 4), two different
de-escalation strategies are compared in patients who
respond to the treatment.
Randomization procedures
Randomization lists have been generated by the central
study site several months before including the first pa-
tient in the NORD-STAR study, using an online com-
puter program (https://www.randomizer.org/). At
screening, the patient will receive a site-specific, unique
patient number, which stays with the patient throughout
the study. When a patient is found eligible, the central
study site will be contacted by the local investigator via
telephone or e-mail. Allocation of patients to study arm
is done by the central study site at the time of inclusion
(baseline of TP1) and to de-escalation strategy upon ini-
tiation of TP2. In TP1, patients are scheduled for a base-
line visit where they are randomly allocated on a 1:1:1:1
ratio to one of four different treatment arms (Table 1).
Stratification will be performed by country, gender and
anti-citrullinated peptide antibody (ACPA) status (posi-
tive/negative). After allocation, a confirming receipt is
sent to the local investigator via e-mail.
Assessment of disease activity and treatment response
Disease activity and treatment response are assessed by
the Clinical Disease Activity Index (CDAI), which is a
composite score of a 28 swollen joint count (SJC), a 28
tender joint count (TJC), patient global disease activity
(assessed by the patient on a scale from 0 to 10 where
10 is maximal activity) and evaluator’s global disease
activity (assessed by the evaluator on a scale from 0 to
10 where 10 is maximal activity). The CDAI score is
interpreted as follows: remission: ≤2.8, low disease activ-
ity: >2.8 and ≤10, moderate disease activity: >10 and
≤22, high disease activity: >22.
Treatment strategy in TP1 and TP2
In all treatment arms of TP1, the patients receive
methotrexate, escalated to 25 mg/week within 1 month.
To this is added either sulphasalazine + hydroxychloro-
quine + i.a. glucocorticoids (arm 1A, applied in Denmark
and Finland) or orally administered prednisolone (arm 1B,
applied in Iceland, Norway and Sweden) or one of three
different bDMARD therapies (arm 2: certolizumab-pegol;
arm 3: abatacept; arm 4: tocilizumab). Glucocorticoids i.a.
are administered when clinically indicated (or for arm 1A,
whenever a swollen joint is detected at a visit), but not
4 weeks prior to every time point for clinical outcome
evaluation (weeks 20–24, 44–48, 52–56, 64–68 and 76–80
from baseline in TP1).
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At 48 weeks from baseline, patients who have been in
CDAI remission over the preceding 24 consecutive
weeks will enter TP2. Patients not fulfilling this criterion
will be re-assessed at weeks 56, 68 and 80. If the patient
has not fulfilled CDAI remission over 24 consecutive
weeks by week 80, the patient exits the study and the pa-
tient is scheduled for a follow-up telephone contact
12 weeks after termination.
Patients eligible for TP2 are randomized to either early
(TP2-A) or late (TP2-B) dose reduction followed by dis-
continuation. In both arms, methotrexate is maintained
at an unchanged dose. In TP2-A, de-escalation starts im-
mediately upon entering TP2 and all bDMARDs and
csDMARDs except methotrexate are tapered through
12 weeks and thereafter discontinued, provided that a
flare has not occurred. In TP2-B, the same de-escalation
starts after 24 additional weeks of full medication. Taper-
ing will proceed as follows: dose of sulphasalazine,
hydroxychloroquine and orally administered prednisol-
one will be halved and dose intervals of certolizumab-
pegol, abatacept and tocilizumab will be doubled. If a
flare occurs at any time point (i.e., patient has a CDAI
>2.8), it is recommended to resume the full dose of
study medication until the end of the study. Whether
the patient should resume full medication or not will be
decided by the local investigator at each site. Patients
are followed until 80 weeks from inclusion in TP2. Glu-
cocorticoids i.a. may be administered throughout TP2,
but not 4 weeks prior to every time point for clinical
outcome evaluation (TP2-A: weeks 8–12, 20–24 and
76–80 from the first day in TP2-A; TP2-B: weeks 20–24,
32–36, 44–48 and 76–80 from the first day in TP2-B).
If the patient fails to attend a scheduled visit, the study
site will contact the patient via telephone or e-mail to
schedule a new appointment.
Patients may withdraw from the study at any time and
will be discontinued from the study if they do not re-
ceive a dose of study drug for three consecutive months.
Patients will be withdrawn if any of the following occur:
clinically significant abnormal laboratory results or ad-
verse events (AEs), which rule out continuation of the
study medication, as determined by the investigator;
lack of efficacy (e.g., persisting DAS28 values >5.1, in-
creasing DAS28 values or increasing core set vari-
ables), death, the patient becomes pregnant while on
study medication, other illness that is not compatible
with treatment according to the local investigator,
failure to adhere to the protocol or a clinical course
not acceptable within the normally applied paradigms
of early RA between baseline and 6 months’ follow-
up, as determined by the investigator.
If patients in treatment arm 1B have an unsatisfactory
clinical course at the 6-month visit (or thereafter), the
investigator will have the option of adding sulphasalazine
and/or hydroxychloroquine to the treatment regimen,
without precluding them to continue within the protocol.
This is not possible for patients in other treatment arms.
Since treatment recommendations for clinical practice ad-
vocates a treat-to-target approach in which treatment is
evaluated after 3 months, it will not be considered a
Fig. 1 Flow chart of the phases in treatment part 1 (TP1) of the NORD-STAR study
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protocol violation if patients in the trial have their
csDMARD therapy adjusted after, e.g., 3 months. If the pa-
tient at any stage of the trial terminates the study prema-
turely, the patient will be asked to complete an early
termination visit (Figs. 5, 6 and 7). In addition, a follow-up
telephone contact will be scheduled 12 weeks after the exit.
If a patient does not tolerate orally administered
methotrexate at a dose of 25 mg/week, the investigator
is allowed to reduce the dose or change to subcutane-
ously administered (s.c.) methotrexate. If methotrexate
still cannot be tolerated, the investigator may replace
methotrexate with either leflunomide or azathioprine. If
this adjustment is not tolerated, patients in arms 2, 3
and 4 are allowed to remain on bDMARD treatment as
monotherapy. Patients with persistent failure to tolerate
the assigned drug(s) despite these adjustments will exit
the study and receive standard-of-care treatment.
Acetaminophen, nonsteroidal anti-inflammatory drugs
and tramadol analgesics are allowed as needed through-
out the study.
Patients
Patients diagnosed with early RA (symptom duration
less than 24 months) will be recruited during routine
visits at the rheumatology departments while they are
DMARD-naïve. The study sites will strive to keep clini-
cians informed about the NORD-STAR study to main-
tain a high rate of enrollment. Recruitment of patients
will take place at participating study sites in Denmark,
Finland, Iceland, Norway and Sweden in a competitive
manner, i.e., all active centers recruit until the goal of
800 patients has been reached. No advertising will be
used to recruit patients and participants will not be
compensated economically. The patients will receive oral
and written information about the study. Patients willing
to participate sign a written informed consent and a
screening visit is scheduled to ensure that the patients
meet the criteria for inclusion. For a complete list of
inclusion and exclusion criteria, see Table 2.
Patient follow-up
In TP1, the patients are scheduled for regular outpatient
appointments every second week for the first 8 weeks
(visits at weeks 2, 6 and 20 may be replaced by a telephone
contact), followed by successively increasing intervals be-
tween each visit (Fig. 5). At each visit, joint counts will be
performed by a joint-assessor who is blinded to the pa-
tient’s treatment alternative and not otherwise involved in
the study. Regular clinical assessments, blood samples,
urine samples and patient-reported outcomes will be
carried out as listed in Fig. 5.
In TP2, the patient is scheduled for regular appoint-
ments with the investigator and joint-assessor, as in TP1.
At de-escalation of the study medication, the patient will
attend the clinic every second week (visits at weeks 2, 6,
14, 18, 20 and 28 from initiating de-escalation may be
replaced by a telephone contact) followed by successively
increasing intervals between each visit (Figs. 6 and 7).
Regular clinical assessments, blood samples, urine
Fig. 2 Flow chart of the phases in treatment part 2 (TP2) of the NORD-STAR study
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samples and patient-reported outcomes will be carried
out (Figs. 6 and 7).
Adherence to allocated treatment is monitored by
letting the patients record their use of study drugs in pa-
tient diaries provided by the study sites (Finland, Iceland,
Norway and Sweden) or by asking the patient at each
visit if, and how many doses of, study medication have
not been taken since last follow-up visit (Denmark).
Variables and their assessments
Demographic data and physical examination
At screening, demographic data (age, gender, duration of
symptoms, disease duration, smoking status, alcohol
consumption, medical and surgical history, use of con-
comitant medication) and physical examination (height,
weight, body temperature, respiratory frequency, blood
pressure, pulse frequency, electrocardiogram) will be
carried out (Figs. 5, 6 and 7).
Clinical and laboratory assessments
At all visits (Figs. 5, 6 and 7), tender- and swollen-joint
counts will be carried out. In total, 68 joints will be
assessed for tenderness (temporomandibular, sternoclavi-
cular, acromioclavicular, shoulder, elbow, wrist, 1st to 5th
metacarpophalangeal (MCP), 1st interphalangeal (IP), 2nd
to 5th proximal interphalangeal (PIP), 2nd to 5th distal in-
terphalangeal (DIP), hip, knee, ankle, tarsus, 1st to 5th
metatarsophalangeal (MTP), 1st IP and 2nd to 5th PIP
(toes) joints) and 66 joints will be assessed for swelling (all
of the above except the hip joints). CDAI and DAS28-
CRP (C-reactive protein) will be based on assessment of
28 joints (shoulder, elbow, wrist, 1st to 5th MCP, 1st IP, 2nd
to 5th PIP and knee joints) [27].
Standard-of-care blood samples (blood count, uric acid,
creatinine, total bilirubin, alanine/aspartate transaminase,
alkaline phosphatase, sodium, potassium, calcium, albumin,
cholesterol, triglycerides, CRP and erythrocyte sedimenta-
tion rate (ESR, not assessed in Denmark)) will be obtained.
At screening, patients are screened for hepatitis B, C and
tuberculosis (purified protein derivate (PPD) or Quanti-
feron test). Furthermore, samples will be analyzed for
rheumatoid factor, ACPA, anti-nuclear antibodies (ANA) at
screening and at initiation of TP2 and, if clinically indicated,
also throughout the study. If ANA is positive, anti-double-
stranded deoxyribonucleic acid (dsDNA) will be analyzed.
Urine samples will be analyzed for ketones, pH, protein,
red blood cells, white blood cells, nitrate and glucose. For
women with childbearing potential, urine or serum human
chorionic gonadotropin will be analyzed at each visit. Blood
and urine samples will be obtained for biobank storage at
several visits (Figs. 5, 6 and 7).
Patient-reported outcomes
At each visit (Figs. 5, 6 and 7), the patient’s assessment of
pain, fatigue and global impact of RA and also the physi-
cian’s global assessment of disease activity will be recorded
on Visual Analogue Scales (VAS 0–100). Duration of morn-
ing stiffness will be recorded. Physical function will be
assessed using a Health Assessment Questionnaire (HAQ)
[28]. Work-related issues will be assessed using the Work
Productivity and Activity Impairment (WPAI) question-
naire [29]. Level of fatigue is assessed using the Functional
Fig. 3 Overview of the NORD-STAR study, treatment part 1. Abbreviations: TP1 treatment part 1, ACT aggressive conventional synthetic
disease-modifying antirheumatic therapy, TNF tumor necrosis factor, ABA abatacept, TCZ tocilizumab, W week
Glinatsi et al. Trials  (2017) 18:161 Page 6 of 17
Assessment of Chronic Illness Therapy (FACIT) fatigue
scale [30]. Health-related quality of life is assessed using
the EuroQol 5 dimensions (EQ5D) [31] and the Short
Form 36 Health Survey Questionnaire (SF36, only
performed at certain visits) [32]. Patient Acceptable
Symptom State (PASS) will be used to measure the
minimal clinical acceptable state of each patient [33].
Conventional radiography
Conventional radiographs of the chest will be obtained
at baseline to rule out the presence of tuberculosis or
other clinically significant conditions. Conventional ra-
diographs of hands and feet will in TP1 be obtained at
screening, weeks 24, 48 and 80 should the patient re-
main in TP1 at this time point. In TP2, conventional ra-
diographs will be obtained at the initiation (not
necessary if the patient has undergone the procedure
within 12 weeks), after 24 weeks, and at all exits from
the study. The radiographs will be analyzed for bone
erosion and joint space narrowing using the Sharp van
der Heijde (SvH) score [34]. The radiographs will be
assessed with known chronology by two independent
readers, blinded to all clinical data.
Outcomes
Primary outcomes
The primary clinical outcome in TP1 is the proportion
of patients in remission at week 24 according to the
CDAI criteria (i.e., CDAI ≤2.8) [35] which will be com-
pared between the four different treatment groups. The
primary clinical outcome in TP2 is the proportion of
patients in remission according to the CDAI criteria
24 weeks after tapering of study medication was initi-
ated, which will be compared between the two different
tapering groups (i.e., week 24 in TP2-A and week 48 in
TP2-B). The primary radiographic outcome is the
change of the total SvH score [34] after 48 weeks.
Secondary outcomes
Secondary outcomes include the proportion of patients in
remission at weeks 24 in TP2 according to the CDAI cri-
teria. Furthermore, the following parameters will be
assessed at all time points: CDAI/SDAI (Simplified Disease
Activity Index) [35]/2010 American College of Rheumatol-
ogy (ACR)/EULAR [36] remission, ACR20/ACR50/ACR70/
ACR-hybrid, DAS28-ESR (values, DAS28-ESR-based dis-
ease categories and EULAR responses), DAS28-CRP
(values, DAS28-CRP categories and EULAR responses),
SDAI/CDAI values, core set variables (66/68 joint count),
FACIT fatigue score and VAS fatigue, WPAI, EQ5D, HAQ,
SF36, PASS, morning stiffness, patient VAS for disease ac-
tivity and pain and physician VAS for disease activity.
Secondary radiographic outcomes include (for all rele-
vant time points) change in SvH score, change in SvH
erosion score, change in SvH joint space narrowing
score, proportion of patients without radiographic
Fig. 4 Overview of the NORD-STAR study, treatment parts 2 A and B. Abbreviations: TP2 treatment part 2, DR dose reduction, W week, MTX
methotrexate, BL baseline
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progression and reduction of predicted progression ac-
cording to the published POPERA model [37].
Statistics
Sample size and power considerations
In order to achieve a power of 85% for detecting any dif-
ference between the four treatment arms by an overall
chi-square test with a type I error of 0.05, a sample size of
724 is required. In order to achieve a power of 90% for an
overall chi-square test of any difference between the four
treatment arms with a type I error of 0.05, a sample size
of 832 is required. In the NORD-STAR study, a sample
size of 800 patients has been selected. The power calcula-
tion is based on previously published data.
Statistical analysis plan
The NORD-STAR study will be conducted according to
the modified intention-to-treat (mITT) principle, and
the mITT population will be defined as all patients re-
ceiving at least one dose of study medication. Demo-
graphic information and baseline characteristics of these
patients will be summarized by count and percentages
for discrete variables and by summary statistics (mean,
standard deviation, etc.) for continuous variables.
The percentage of responders at each study visit will
be summarized using nonresponder imputation (missing
responses will be counted as nonresponse). Continuous
measurements will be summarized using both observed
and imputed method by study visit. AEs will be summa-
rized by number and percentage of patients experiencing
the AE including the rate of AEs normalized by the
study drug exposure. Laboratory measurements and vital
sign measurements will be summarized by summary sta-
tistics and shift tables as appropriate.
The null hypothesis of no difference in TP1 between
responder percentages in arms 1, 2, 3 and 4 will be
tested using a two-sided analysis of variance (ANOVA)
test at a significance level of alpha = 0.05, followed by
testing according to Bonferroni-Dunn. Pairwise compari-
sons of the difference of proportions in CDAI remission
are done sequentially in two steps:
Step 1: csDMARD therapy (arm 1) versus bDMARD
therapy (arms 2, 3 and 4), at 0.05/3, two-sided significance
level. If there is at least one significant result, go to step 2.
Otherwise stop pairwise testing
Step 2: compare arms 2, 3 and 4 in a pairwise fashion
at 0.05/3, two-sided significance level
As a secondary outcome, the results obtained with
conventional therapy in Denmark and Finland (using
triple csDMARD therapy + glucocorticoid injections) will
Table 1 Summary of the different treatment arms applied in the NORD-STAR study
All patients: MTX, starting at 10 or 15 mg/week, escalated by 5 mg/week to 25 mg/week within 4 weeks.
To this is added 1 of 4 treatment arms below.
ARM 1A:
Aggressive csDMARD therapy followed by
the investigators in Denmark and Finland:
MTX + SSZ + HCQ + i.a. glucocorticoids
SSZ: 1 g/day (first week), 2 g/day (second week and on)
HCQ: 35 mg/kg/weeka
i.a. injections of triamcinolonhexacetonid: 20 mg/mL or equivalent
(maximum 4 joints or 4 ml per visit).
Injections must be given whenever clinically swollen joints are present.
Priority to larger joints. Orally administered glucocorticoid is not allowed
ARM 1B:
Aggressive csDMARD therapy followed by the
investigators in Iceland, Norway and Sweden:
MTX + p.o. glucocorticoids
Prednisolone: initially 20 mg/day, subsequently tapered in 9 weeks to 5 mg/day
and discontinuation after 9 months.
Glucocorticoid injections (i.a.) of triamcinolonhexacetonid, 20 mg/mL or equivalent
is allowed when clinically indicated
ARM 2:
bDMARD agent 1:
MTX + certolizumab-pegol
Certolizumab-pegol: 400 mg s.c. given at 0, 2 and 4 weeks, thereafter 200 mg
s.c. every other week.
Glucocorticoid injections (i.a.) of triamcinolonhexacetonid, 20 mg/mL or equivalent
is allowed when needed during the first 12 weeks. Thereafter, one to two injections
(2 ml total or 40 mg) every 12 weeks.
Orally administered glucocorticoid is not allowed
ARM 3:
bDMARD agent 2:
MTX + abatacept
Abatacept: 125 mg s.c. every week.
Glucocorticoid injections (i.a.) of triamcinolonhexacetonid, 20 mg/mL or equivalent is allowed
when needed during the first 12 weeks. Thereafter, one to two injections (2 ml total or 40 mg)
every 12 weeks.
Orally administered glucocorticoid is not allowed
ARM 4:
bDMARD agent 3:
MTX + tocilizumab
Tocilizumab: 8 mg/kg i.v. every 4 weeks or 162 mg s.c. every week.
Glucocorticoid injections (i.a.) of triamcinolonhexacetonid, 20 mg/mL or equivalent is allowed
when needed during the first 12 weeks. Thereafter, one to two injections (2 ml total or 40 mg)
every 12 weeks.
Orally administered glucocorticoid is not allowed
aIn Denmark and Finland the patients receive the standard-of-care dose of 200 mg/day and 200–300 mg/day respectively, since other doses are
not available
Abbreviations: bDMARD biological disease-modifying antirheumatic drugs, csDMARD conventional synthetic disease-modifying antirheumatic drugs, MTX,
methotrexate, SSZ sulphasalazine, HCQ hydroxychloroquine, i.a. intra-articular, s.c. subcutaneous, i.v. intravenous, p.o. per os
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Fig. 5 Schedule of enrollment, interventions and assessments in the NORD-STAR study, treatment part 1. *This visit may be replaced by a telephone
contact. **Measured if clinically indicated. ***Blinding of joint-assessor is not necessary since the patient has not been randomized to a treatment arm
at screening. ****If tocilizumab is given intravenously, the weight is measured at all visits. Abbreviations: ET early termination, MTX methotrexate,
SSZ sulphasalazine, HCQ hydroxychloroquine, i.a. intra-articular, CZP certolizumab-pegol, ABA abatacept, TCZ tocilizumab, RA rheumatoid arthritis,
SJC swollen joint count, TJC tender joint count, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, ANA anti-nuclear antibody, PPD purified
protein derivate, VAS Visual Analogue Scale, HAQ Health Assessment Questionnaire, WPAI, Work Productivity Activity Impairment, EQ5D EuroQol
5 dimensions, PASS, Patient Acceptable Symptom State, FACIT Functional Assessment of Chronic Illness Therapy, SF36 Short Form 36, CDAI
Clinical Disease Activity Index, DAS Disease Activity Score
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be compared against conventional therapy in Norway,
Sweden and Iceland (using methotrexate + p.o. glucocor-
ticoids), by ANOVA.
In a secondary analysis the noninferiority hypothesis
for csDMARD therapy versus bDMARD therapy will be
analyzed with an allowable inferiority margin of 5%, and
as exploratory analyses with margins of 10% and 20%.
As a secondary “sensitivity” analysis, the results in TP2
will also be calculated for those patients who during the
preceding 24 weeks simultaneously were in CDAI remis-
sion and had no swollen joints.
Data registration and monitoring
All data will be collected on standardized paper or elec-
tronic Case Report Forms (CRF) as follows: Denmark,
electronic CRF (the DANBIO platform [38]); Finland,
paper CRF; Iceland, electronic CRF (the ICEBIO platform);
Norway, electronic CRF (Viedoc 4); Sweden, paper CRF.
Patients included in the study will be identified by their
unique patient numbers. The protocol has been approved
by the Swedish Data Protection Authority as the trial is
coordinated from Sweden. Study investigators will have ac-
cess to the datasets generated in the study. Protocol,
Fig. 6 Schedule of enrollment, interventions and assessments in the NORD-STAR study, treatment part 2A. *This visit may be replaced by a telephone
contact. **Measured if clinically indicated. ***If tocilizumab is given intravenously, the weight is measured at all visits. Abbreviations: ET early
termination, SJC swollen joint count, TJC tender joint count, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, ANA anti-nuclear
antibody, VAS Visual Analogue Scale, HAQ Health Assessment Questionnaire, WPAI Work Productivity Activity Impairment, EQ5D EuroQol 5 dimensions,
PASS Patient Acceptable Symptom State, FACIT Functional Assessment of Chronic Illness Therapy, SF36 Short Form 36, CDAI Clinical Disease Activity
Index, DAS Disease Activity Score
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protocol amendments, investigator’s brochure, informed
consent and all study-related documents has been
reviewed by an Institutional Review Board and a GCP
(Good Clinical Practice)-certified person. All participating
sites will be monitored before, during and after the trial by
GCP-trained personnel in order to ensure compliance with
GCP, the protocol and all other applicable regulations.
Communication between study sites
The coordinating study center in Sweden can be con-
tacted via e-mail or telephone during working hours.
Important note-to-file and protocol modifications are
communicated to the participating study sites through
e-mail newsletters from the coordinating study center
and are made available as amendments at the NORD-
STAR Internet website.
Publications
All planned study outcomes, positive as well as negative
and inconclusive, will be published in high-impact, peer-
reviewed journals, and the manuscript will be written by
authors fulfilling the authorship criteria as recom-
mended by the International Committee of Medical
Journal Editors.
Fig. 7 Schedule of enrollment, interventions and assessments in the NORD-STAR study, treatment part 2B. *This visit may be replaced by a telephone
contact. **Measured if clinically indicated. ***If tocilizumab is given intravenously, the weight is measured at all visits. Abbreviations: ET early
termination, SJC swollen joint count, TJC tender joint count, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, ANA anti-nuclear
antibody, VAS Visual Analogue Scale, HAQ Health Assessment Questionnaire, WPAI Work Productivity Activity Impairment, EQ5D EuroQol 5 dimensions,
PASS Patient Acceptable Symptom State, FACIT Functional Assessment of Chronic Illness Therapy, SF36 Short Form 36, CDAI Clinical Disease Activity
Index, DAS Disease Activity Score
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Adverse events
An AE is defined as any untoward medical occurrence in
a subject or clinical investigation subject administered a
pharmaceutical product and which does not necessarily
have a causal relationship with this treatment. All AEs will
be registered by the investigator at all visits from the ad-
ministration of the first dose of study drug to 12 weeks
following the administration of the last dose of study drug.
The investigator will register the date of onset, description
of the event, level of severity (mild, moderate or severe),
duration and outcome. Potential relationship with study
drugs will be assessed. Serious adverse events (SAEs) in-
clude death of the patient, life-threatening events,
hospitalization of the patient or prolongation of
hospitalization, congenital abnormality, spontaneous or
elective abortion, persistent or significant disability/incap-
acity and important medical events requiring medical or
surgical intervention to prevent serious outcomes. All
SAEs will be reported to the central study coordinating
team within 24 h of the site being made aware of the SAE.
The central study coordinating team will judge whether
the reported event should be judged as an SAE or a sus-
pected unexpected serious adverse reaction (SUSAR). A
SUSAR will be reported to all participating sites within
7 days for potential lethal SUSARs and within 15 days for
all other SUSARs. The SAEs will be presented in a yearly
report to the national health authorities and ethical com-
mittees by each national coordinating investigator, in ac-
cordance with the GCP guidelines. All AEs and SAEs will
be followed until resolution or stabilization.
Discussion
The NORD-STAR study is, to our knowledge, the first in-
vestigator-initiated randomized trial to compare aggressive
Table 2 Inclusion and exclusion criteria of the NORD-STAR
study
Inclusion criteria
Age ≥18 years
RA according to ACR/EULAR 2010 criteria [55]
< 24 months from arthritis symptom onset
RF positive and/or ACPA positive and/or CRP ≥10 mg/L
DAS28 CRP >3.2 [56]
≥ 2 swollen and ≥2 tender joints (based on a 66/68 joint count) [27]
Female patients are either not of childbearing potential or use birth
control (IUD, contraceptives or have a vasectomized partner)
Female patients should have a negative serum or urine pregnancy
test upon screening
Judged to be in good general health based on medical history,
physical examination, laboratory profile, chest X-ray and
electrocardiogram
Willingness to provide written informed consent
Willingness to administer s.c. injections or receive these by trained
personnel
Exclusion criteria
Previous DMARD therapy for rheumatic diseases
Current active inflammatory joint disease other than RA
Received prednisone (or equivalent) dose >7.5 mg/day or dose
adjustment within the preceding 4 weeks
Received i.a. or parenteral administration of glucocorticoids within the
preceding 4 weeks
Undergone joint surgery within the preceding 2 months (at joints
assessed in the study)
Diagnosed with chronic arthritis before age of 17 years
History with allergic reactions or significant sensitivity to constituents
of study drugs
Treated with any investigatory drugs within the preceding month
Active infection of any kind (except fungal infections of nail beds)
Active infection or infection requiring hospitalization within 4 weeks
of screening
Poorly controlled medical condition which, in the opinion of the
investigator, would put the subject at risk by participation in the study
History of clinically significant hematologic, liver or renal disease
Neurologic symptoms suggestive of CNS demyelinating disease and/
or diagnosis of central demyelinating disease
History of cancer or lymphoproliferative disease (successfully treated
cutaneous squamous cell or basal cell carcinoma, localized carcinoma
in situ of the cervix and curatively treated malignancy >5 years prior
to screening are allowed)
History of listeriosis/histoplasmosis/untreated tuberculosis or persistent
chronic infections, or recent active infections requiring hospitalization or
treatment with i.v. anti-infectives within 30 days or orally administered
anti-infectives within 14 days prior to baseline visit
Latent tuberculosis
Severely immunocompromised
Female patients who are breastfeeding, pregnant or considering
becoming pregnant during the study or within 150 days after the
last dose of study medication
Table 2 Inclusion and exclusion criteria of the NORD-STAR
study (Continued)
Male patients who are planning to father a child during the time they
are included in the study
Clinically significant drug or alcohol usage during the preceding year
Chronic widespread pain syndrome
Considered by the investigator to be an unsuitable candidate for the
study
Unwilling to comply with study protocol
Abnormal screening laboratory results (ASAT/ALAT >1.75 times ULN,
positive serum hCG, positive test for hepatitis B and/or C, creatinine
levels >2 times ULN, hemoglobin <90 g/L, absolute neutrophil count
<1.5 × 103/μL, serum total bilirubin ≥1.5 mg/dL)
Abbreviations: RA rheumatoid arthritis, ACR American College of Rheumatology,
EULAR European League Against Rheumatism, RF rheumatoid factor, ACPA
anti-citrullinated peptide antibody, CRP C-reactive protein, DAS Disease Activity
Score, IUD intra-uterine device, s.c. subcutaneous, DMARD disease-modifying
antirheumatic drugs, i.a. intra-articular, i.v. intravenous, ASAT aspartate transaminase,
ALAT alanine transaminase, ULN upper limit of normal, hCG human
chorionic gonadotropin
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csDMARD therapy and three bDMARD treatments head
to head in early RA, and to compare different methods of
de-escalation.
In TP1 of the trial, the efficacy of four different treat-
ments, or modes of action, in early RA are compared.
Despite rapid development of new treatments for RA,
the optimal treatment choice in the early stage of disease
is not clear. Whereas several bDMARDs, with different
modes of action, are all effective in early and later stages
of disease, only few trials have compared these drugs
head to head. In a randomized noninferiority study of
established RA, two different TNF-blocking agents, eta-
nercept and adalimumab, were compared and no signifi-
cant difference was found [39]. In two randomized
controlled trials (RCTs) in RA patients with inadequate
response to methotrexate, AMPLE and ADACTA, adali-
mumab was compared to abatacept and tocilizumab,
respectively. Adalimumab and abatacept were equally ef-
fective in terms of clinical, functional and radiographic
outcomes when added to methotrexate [40]. Superior
clinical response was achieved with tocilizumab mono-
therapy compared to adalimumab monotherapy in pa-
tients who were intolerant to, or not candidates for,
methotrexate use [41]. The ATTEST trial showed com-
parable clinical results with infliximab and abatacept in
RA patients who had inadequate response to methotrex-
ate. However, fewer infections and SAEs were seen in
the abatacept group [42].
Several papers have been published with indirect pair-
wise comparisons or network meta-analyses, using stat-
istical methods to combine data from different RCTs
and making comparisons across treatments. In these
analyses, most novel antirheumatic drugs, with the excep-
tion of anakinra, showed comparable clinical responses in
combination with methotrexate [43, 44]. Indirect compari-
sons, however, have several limitations, and power and
precision is dependent on the effective number of trials,
sample size and heterogeneity of study populations. In the
NORD-STAR trial, different treatments will be compared
head to head, and the possibility that one or more treat-
ments will emerge as particularly suitable for induction-
maintenance types of therapies could alter the current
paradigms for treating RA.
The NORD-STAR protocol compares aggressive
csDMARD therapy with three bDMARD therapies with
different modes of action; certolizumab-pegol inhibits
TNF, abatacept is a selective T-cell co-stimulation modu-
lator and tocilizumab blocks interleukin 6. There are
currently other treatment options available with other
modes of actions, including rituximab, a monoclonal
antibody that targets CD20-positive B-cells, and tofaciti-
nib, a small molecule drug inhibiting Janus kinase (JAK)
given orally. Both rituximab and tofacitinib are also ef-
fective in RA [45, 46]. An optimal trial design would
include these treatments. However, it was not feasible to
include additional treatment arms due to sample size
considerations (i.e., the current four-armed design re-
quired 800 patients to be included). Furthermore, rituxi-
mab is administered twice 14 days apart and then again
after 6–12 months, which would have been difficult to fit
into the study design. Tofacitinib had not been approved
by the EMA (European Medicines Agency) and was,
therefore, not marketed in the Scandinavian countries at
the time when the study was planned.
The trial involves rheumatology centers in five differ-
ent countries and patients are treated in routine care, ac-
cording to protocol. The study has been pragmatically
designed to ensure that the treatment algorithms used
are easily transferable to daily clinical practice. As an ex-
ample, there are two alternative treatment regimens in
the active csDMARD treatment arm due to different
treatment practice in the Nordic countries. Triple therapy
with methotrexate, sulphasalazine and hydroxychloro-
quine in combination with aggressive use of intra-articular
glucocorticoid injections (treatment arm 1A) is widely
used in Finland and Denmark, whereas in Sweden,
Norway and Iceland methotrexate in monotherapy com-
bined with orally administered prednisolone and intra-
articular glucocorticoid injections is more commonly used
(treatment arm 1B). Both treatment strategies have been
shown to be more effective than single-DMARD therapy
[6, 47, 48]. The route of administration of tocilizumab and
abatacept is another example of the pragmatic approach.
When subcutaneous formulations became available, the
protocol was modified to include both intravenous (i.v.)
and s.c. administration routes. The decision was sup-
ported by a noninferiority trial where i.v. and s.c. routes of
tocilizumab and abatacept administration were equally
effective [49, 50].
Treat-to-target and tight control are two well-established
principles in management of patients with early RA [13, 51]
that are included in the current study design. Patients who
do not achieve CDAI remission in TP1 will exit the study.
TP2 implies a dynamic strategy where treatment is modi-
fied as long as a response target is not reached. The pri-
mary goal in this trial is to compare aggressive csDMARD
therapy and bDMARD therapies, thus the protocol does
not allow for major treatment changes. However, a tight
follow-up regimen is applied, and intra-articular injections
can be given in swollen joints at the discretion of the phys-
ician throughout the trial (although with upper limits).
Additionally, after 6 months, sulphasalazine and hydroxy-
chloroquine can be added to methotrexate in treatment
arm 1B, if clinically indicated.
In NORD-STAR, the idea is to treat the disease ag-
gressively in the early phase of disease, and a step-down,
rather than a step-up, strategy is applied. In the second
part of the study two different tapering strategies are
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compared. In previous trials, withdrawals of biologic
therapy were associated with a subsequent disease flare in
50–90% of patients with established disease [20, 22, 23].
Dose reduction, on the other hand, may be applied in
patients in a low disease activity state, as shown with eta-
nercept in the randomized PRESERVE and DOSERA trials
[21, 23]. In patients with early RA, good response can be
maintained in a larger proportion of patients upon discon-
tinuation of anti-TNF agents [26], supporting the idea of a
window of opportunity. The AVERT trial even demon-
strated that induction therapy with abatacept and metho-
trexate in early RA resulted in sustained remission in a
small proportion of patients up to 18 months after discon-
tinuation of all RA treatment [24]. However, the PRIZE
study showed that remission was lost in a substantial pro-
portion of early RA patients upon withdrawal of etaner-
cept [52]. Thus, the concept of induction-maintenance
therapy in early RA is still up for debate.
The degree of suppression of disease activity seems to
be a predictor for successful tapering of bDMARD
drugs. In the HONOR trial, deep remission (DAS28 <
1.98) was associated with maintenance of response after
withdrawal of adalimumab [53]. In NORD-STAR, we
recruit DMARD-naïve patients with early disease. Sus-
tained CDAI remission, which is a stringent remission
criterion, is required to start treatment tapering. The ap-
propriate time point to start de-escalation in patients
who are in stable remission is not known. In part 2 of
the NORD-STAR study we address this question.
The NORD-STAR study has an open-label design,
where both the investigator and the patient know to
which treatment arm the patient belongs. However, in
order to allow head-to-head comparison between the
different treatments arms, blinding in some fashion is
essential in order to avoid biased results. This is solved
by having the joint counts performed by blinded asses-
sors, not otherwise involved in the study. The joint
count is part of the CDAI score, which is the primary
outcome. The primary radiographic outcome will be the
difference in the SvH score, which will be evaluated
using assessors blinded for all clinical and treatment
data. Hence, the risk of bias is reduced.
CDAI was chosen as the primary clinical outcome for
several reasons. First of all, according to treat-to-target
guidelines, remission is the main treatment goal in RA
[51]. Secondly, CDAI is a composite score that does not
include ESR and CRP [54], which is important since
tocilizumab is known to suppress these inflammatory
markers irrespective of the clinical response. Further-
more CDAI ≤2.8 is a stringent remission criterion redu-
cing the risk of residual inflammation.
The ultimate goal in RA management is to prevent
loss of function. Both inflammation and structural dam-
age contribute to loss of function. In several studies,
bDMARD therapies have been shown as particularly effi-
cient in halting radiographic progression. Thus, a pri-
mary radiographic endpoint is included in the study.
The trial is conducted as a unique collaboration of
rheumatology centers across the Nordic countries. An
International Steering Committee comprises rheumatol-
ogy experts from all the Nordic countries, each with ex-
perience from clinical trials. The committee has regular
meetings and is jointly responsible for the study design
and major decisions regarding the trial. However, each
country is separately responsible for funding, regulatory
approvals and conduction of the trial. As a result, patient
recruitment will be initiated at different time points in
the five participating countries.
Karolinska Institute is sponsor of the trial and a cen-
tral study team is situated in Stockholm. The central
study team is, e.g., responsible for handling of SUSARs,
producing annual reports for the medical agencies, and
for updating the NORD-STAR Internet site. Other
responsibilities have been delegated to the national
managements.
Feasible data collection within the frame of daily clin-
ical practice has been important in this trial. Therefore,
the use of already established clinical tools has been en-
couraged for CRF purposes. In Denmark and Iceland,
the DANBIO/ICEBIO national registers, which are used
routinely at all departments of rheumatology across the
two countries, serves as the eCRF. Norway use Viedoc, a
web-based solution for clinical trial data collection and
management that complies with all relevant regulations
in North America, Europe and Japan, including 21 CFR
Part 11, CSUCI, ICH GCP, CDISC, HIPAA, PuL and EU
Annex 11, whereas in Sweden and Finland paper CRFs
have been chosen for data collection.
Several spin-off projects have been approved by the
International Steering Committee, including use of ultra-
sonography, magnetic resonance imaging and biomarker
studies. A complete list of current spin-off projects is
available at the NORD-STAR Internet site and listed in
Additional file 2.
Due to the use of unique personal registration num-
bers of all inhabitants of the Nordic countries, the study
data may be linked to national registers on, e.g., cancer,
hospitalization, and socioeconomics with the potential
to gain additional knowledge about the long-term im-
pact of the different treatments. Also, health economic
calculations can be conducted.
In conclusion, the NORD-STAR trial seeks to identify
which treatment strategy should be applied in early RA.
The trial aims at identifying the best remission-
induction therapy, but also to improve de-escalation
strategies. The pragmatic design ensures good external
validity of the results. Hopefully, NORD-STAR will
contribute to improved outcomes, both for individual
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patients, and for society at large, by reducing direct and
indirect costs of treatments.
Trial status
Recruitment started in December 2012 and the trial is
still recruiting.
Additional files
Additional file 1: A completed SPIRIT Checklist. (PDF 97 kb)
Additional file 2: A complete list of current spin-off projects. (PDF 173 kb)
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